reports
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Ful...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q4 and Full Year of 2025 PORTLAND, Maine, Jan. 08, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, today announced preliminary, unaudited sales results for the fourth quarter and full year of 2025. Since the first quarter of 2020, ImmuCell has been providing a preliminary look at its unaudited top line results soon after the close of the quarter and the Company expects...
ImmuCell to Conduct Conference Call with Investors to Discuss Strategi...
ImmuCell to Conduct Conference Call with Investors to Discuss Strategic Change in Focus Conference Call Scheduled for Friday, January 9, 2026 at 9:00 AM ET PORTLAND, Maine, Jan. 07, 2026 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity, plans to conduct a conference call with investors on Friday, January 9, 2026 at 9:00 AM ET. The Company first announced a strategic change in focus in favor of the First Defense® product line and awa...
ImmuCell Announces Strategic Focus on First Defense® After Receiving a...
ImmuCell Announces Strategic Focus on First Defense® After Receiving an FDA Incomplete Letter for Re-Tain® PORTLAND, Maine, Dec. 24, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell”), an animal health company that develops, manufactures and markets products that improve cattle health and productivity today announced that it received an Incomplete Letter from the United States Food and Drug Administration (FDA) on December 23, 2025 for its Re-Tain® New Animal Drug Application (NADA), and simultaneously that it is increasing its First Defense® field sales force by 50...
Immucell Corp: 1 director
A director at Immucell Corp maiden bought 9,738 shares at 5.092USD and the significance rating of the trade was 70/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years cl...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended S...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2025 PORTLAND, Maine, Nov. 13, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2025. Product Sales Highlights: During the third quarter of 2025, product sales decreased by 8% to approximately $5.5 m...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended September 30, 2025 Conference Call Scheduled for Friday, November 14, 2025 at 9:00 AM ET PORTLAND, Maine, Nov. 06, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended September 30, 2025 after the market closes on Thursday, Novembe...
ImmuCell Announces Onboarding of New CEO and Related Management Change...
ImmuCell Announces Onboarding of New CEO and Related Management Changes PORTLAND, Maine, Nov. 04, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced the start date of its new CEO and related board changes. Effective November 1, 2025, Olivier te Boekhorst began serving as President and CEO of the Company, succeeding Michael F. Brigham. At its meeting o...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025
ImmuCell Announces Preliminary, Unaudited Sales Results for Q3 of 2025 PORTLAND, Maine, Oct. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the third quarter of 2025. Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the close...
ImmuCell Announces Selection of its Next President and CEO
ImmuCell Announces Selection of its Next President and CEO PORTLAND, Maine, Sept. 29, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has selected Olivier te Boekhorst as its next President and CEO. The Company anticipates a start date of November 1, 2025 for Mr. te Boekhorst. Mr. te Boekhorst is currently an Operating Partner at ARCHIMED, ...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended J...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended June 30, 2025 PORTLAND, Maine, Aug. 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended June 30, 2025. Product Sales Highlights: During the second quarter of 2025, product sales increased by 18% to approximately $6.4 million c...
ImmuCell Announces Bank Debt Refinancing
ImmuCell Announces Bank Debt Refinancing PORTLAND, Maine, Aug. 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced it has successfully refinanced a portion of its bank debt. Management’s Discussion: Proceeds from a new loan from Maine Community Bank (MCB) in the principal amount of $2,327,119, bearing interest at a fixed rate of 6.5% per annum, we...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended June 30, 2025 Conference Call Scheduled for Friday, August 15, 2025 at 9:00 AM ET PORTLAND, Maine, Aug. 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended June 30, 2025 after the market closes on Thursday, August 14, 2025. T...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025
ImmuCell Announces Preliminary, Unaudited Sales Results for Q2 of 2025 PORTLAND, Maine, July 09, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the second quarter of 2025. Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the cl...
ImmuCell Embarks on CEO Succession Planning Process
ImmuCell Embarks on CEO Succession Planning Process PORTLAND, Maine, June 25, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has commenced a search for a successor in the position of President and CEO. “I turn 65 this fall and have told my fellow Directors that I would like to retire from full-time work by early 2026,” said Michael F. Br...
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders
ImmuCell to Hold Virtual-Only Annual Meeting of Stockholders PORTLAND, Maine, June 05, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that its 2025 Annual Meeting of Stockholders (the “Annual Meeting”) will be conducted virtually on Thursday, June 12, 2025, at 9:30 AM ET, as previously disclosed in its Proxy Statement that was filed with the Securi...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended M...
ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2025 PORTLAND, Maine, May 14, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended March 31, 2025. Product Sales Highlights: Product sales during the first quarter of 2025 increased by 11% to approximately $8.1 millio...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended...
ImmuCell to Announce Unaudited Financial Results for the Quarter Ended March 31, 2025 Conference Call Scheduled for Thursday, May 15, 2025 at 9:00 AM ET PORTLAND, Maine, May 12, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, expects to report unaudited financial results for the quarter ended March 31, 2025 after the market closes on Wednesday, May 14, 2025. The...
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025
ImmuCell Announces Preliminary, Unaudited Sales Results for Q1 of 2025 PORTLAND, Maine, April 08, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced preliminary, unaudited sales results for the first quarter of 2025. Since the first quarter of 2020, the Company has been providing a preliminary look at its unaudited top line results soon after the clos...
ImmuCell Hires Chief Financial Officer
ImmuCell Hires Chief Financial Officer PORTLAND, Maine, April 07, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it has hired Timothy C. Fiori to serve as its Chief Financial Officer. Mr. Fiori brings to ImmuCell approximately 24 years of finance and commercial operating experience with IDEXX Laboratories in Westbrook, Maine. He is a 2001 gra...
ImmuCell Announces Initiation of Investigational Product Use of Re-Tai...
ImmuCell Announces Initiation of Investigational Product Use of Re-Tain® PORTLAND, Maine, April 02, 2025 (GLOBE NEWSWIRE) -- ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that it is initiating Investigational Product use of Re-Tain®. The Company intends to use this opportunity to test market acceptance of the product through a controlled launch. This initiative also help...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.